Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion
Open Access
- 23 November 2007
- journal article
- review article
- Published by Wiley in Vox Sanguinis
- Vol. 94 (2), 87-95
- https://doi.org/10.1111/j.1423-0410.2007.01003.x
Abstract
Two approaches have been used to produce universal group O donor red blood cells (RBCs) from groups A, B, and AB RBCs. The first involves cleavage of the terminal immunodominant sugars from carbohydrate chains on the RBC membrane, using specific enzymes, to produce so-called enzyme-converted group O (ECO) RBCs. ECO RBCs have been produced from whole units of B RBCs and transfused successfully to humans. Group A RBCs (especially A(1) RBCs) have been more difficult. New sources of enzymes have produced ECO RBCs from A(1) and A(2) RBCs that do not react with powerful monoclonal anti-A. Unfortunately, there are still problems encountered with polyclonal human antibodies (i.e. cross-matching). The second approach interferes with an antibody reaching its specific antigen on the RBC membrane by bonding polyethylene glycol (PEG) to the RBC. PEG will attract water molecules, yielding a combination that may block most RBC antigens, including A and B antigens. Initial excitement generated by preliminary reports of the possibility of producing 'stealth' PEG-RBCs were tempered by the findings of in vitro serological problems and possible reduced in vivo RBC survival. Many of these problems were solved, but recent findings that PEG is immunogenic in animals and humans, and that PEG antibodies can shorten the survival of PEG-RBCs (in rabbits) and pegylated proteins (e.g. PEG-asparaginase) in humans, are disturbing, suggesting that 'stealth' RBCs may never become a reality.Keywords
This publication has 41 references indexed in Scilit:
- A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodiesTransfusion, 2004
- Identification, molecular cloning and expression of an α-N-acetylgalactosaminidase gene fromClostridium perfringensFEMS Microbiology Letters, 2002
- Covalent binding of poly(ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosityAmerican Journal of Hematology, 1997
- Purification and Characterization of Blood Group A-degrading Isoforms of α-N-Acetylgalactosaminidase from Ruminococcus torques Strain IX-70Published by Elsevier ,1997
- Conversion of ABO Blood GroupsTransfusion Medicine Reviews, 1989
- Action of α‐galactosidase from Clostridium sporogenes and coffee beans on blood group B antigen of erythrocytes The effect on the viability of erythrocytes in circulationTransfusion, 1983
- A-Active Trisaccharides Isolated from A1 and A2 Blood-Group-Specific GlycoproteinsEuropean Journal of Biochemistry, 1981
- Action of α-galactosidase on glycoprotein from human B-erythrocytesBiochemical and Biophysical Research Communications, 1971
- Immunochemical Studies on Blood Groups.1 XXV. The Action of Coffee Bean α-Galactosidase on Blood Group B and BP1 SubstancesJournal of the American Chemical Society, 1960
- Possible Genetical Pathways for the Biosynthesis of Blood Group MucopolysaccharidesVox Sanguinis, 1959